Rulifast 1.5% Cream 10 gm
Original price was: 2,000.00৳ .1,900.00৳ Current price is: 1,900.00৳ .
Rulifast 1.5% Cream contains ruxolitinib, a JAK inhibitor applied directly to the skin. It treats atopic dermatitis (eczema) and nonsegmental vitiligo. It works on the immune signals that drive itch and inflammation in eczema and pigment loss in vitiligo. Because it is applied to the skin, most of the medicine stays where it is needed and little reaches the bloodstream. It is a non-steroidal option, so it does not cause skin thinning the way long-term topical steroids can. The 10 gm tube suits small treatment areas, such as patches on the face, hands or neck, or a first trial of therapy.
Indications
- Atopic dermatitis (eczema): Short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in patients aged 12 and older whose immune system is not weakened. It is used when other prescription topical treatments haven’t controlled the disease well enough, or aren’t advisable.
- Nonsegmental vitiligo: Topical treatment of nonsegmental vitiligo in patients aged 12 and older, to help restore skin colour (repigmentation).
How it works
Ruxolitinib blocks Janus kinase 1 and 2 (JAK1/JAK2), enzymes that carry inflammatory signals inside immune and skin cells.
- In eczema, this reduces the cytokines that cause itching, redness and inflammation. Itch relief often starts within days.
- In vitiligo, it calms the immune attack on melanocytes, the pigment-producing cells, so the skin can gradually regain its colour.
Dosage and administration
Use only as prescribed by a registered physician, preferably a dermatologist.
Atopic dermatitis:
- Apply a thin layer twice daily to the affected areas, covering up to 20% of body surface area.
- Stop applying it once the signs and symptoms (itch, rash, redness) have cleared.
- If there is no improvement within 8 weeks, see your doctor again.
Nonsegmental vitiligo:
- Apply a thin layer twice daily to the affected skin, covering up to 10% of body surface area.
- Repigmentation is gradual, and a satisfactory response may take more than 24 weeks.
- If there is no meaningful repigmentation by 24 weeks, your doctor should reassess treatment.
Important application advice:
- Do not use more than 60 gm per week, or 100 gm every 2 weeks.
- For external use on the skin only. Not for use in the eyes, mouth or vagina.
- Wash your hands after applying, unless your hands are being treated.
- Do not use it together with other JAK inhibitors, biologic medicines, or strong immunosuppressants such as azathioprine or ciclosporin.
Contraindications
Known hypersensitivity to ruxolitinib or any ingredient of the cream.
Side effects
Atopic dermatitis:
- Common cold symptoms (nasopharyngitis), runny nose
- Diarrhoea
- Bronchitis, tonsillitis, ear infection
- Hives (urticaria), folliculitis
- Raised eosinophil count
Vitiligo:
- Acne at the application site
- Itching or redness at the application site
- Nasopharyngitis, headache, fever
- Urinary tract infection
Drug interactions
- Ruxolitinib is broken down by the liver enzyme CYP3A4. Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir) can raise ruxolitinib levels and the risk of side effects, so avoid using them together.
- CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin) may lower ruxolitinib levels.
- Do not combine with other JAK inhibitors, biologics or strong immunosuppressants.
Pregnancy and breastfeeding
- Pregnancy: There is not enough data on use in pregnancy. Use only if your doctor decides the benefit outweighs the risk.
- Breastfeeding: Do not breastfeed during treatment or for about 4 weeks after the last application.
Paediatric use
Safety and effectiveness have not been established in children under 12 years.
Overdose
No data available. If a large amount is swallowed by accident, seek medical advice.
Storage
Store below 30°C in a dry place, away from sunlight. Do not freeze. Keep the tube tightly closed. Keep out of the reach of children.
Related Products
Out of stock
Out of stock
Out of stock